The original article, which appeared online on 31 January 2026, described laboratory and animal experiments linking buparlisib, an investigational drug that targets the PI3K signaling pathway, to an unexpected mechanism of treatment resistance. According to the paper, exposure to the compound appeared to drive up levels of eukaryotic elongation factor-2, a molecular machine central to protein synthesis in cells. The authors argued that this upregulation contributed to treatment failure in lung cancer cells, a finding that, if confirmed, would have carried implications for how clinicians combine targeted therapies with other anticancer agents.

That conclusion is now formally withdrawn. In the retraction note, the Editor-in-Chief of the journal stated that the article has been retracted because the tumors presented in Figure 5 of the paper exceed the accepted limits for tumor burden. In animal cancer studies, tumor burden refers to the total volume or mass of tumor tissue carried by an experimental animal. Research ethics frameworks impose upper limits on how large tumors may be allowed to grow, both to protect animal welfare and to ensure that experiments remain within humane boundaries. When tumors surpass those limits, the study is considered to have breached the ethical standards under which animal research is permitted.

The editor’s decision was anchored explicitly in the ARRIVE 2.0 reporting guidelines, a widely adopted framework for the design, conduct and publication of animal research. ARRIVE, which stands for Animal Research: Reporting of In Vivo Experiments, was developed to improve the reproducibility and ethical rigor of studies involving animals. The updated 2.0 version, published in 2020 by Percie du Sert and colleagues in the journal PLoS Biology, sets out detailed expectations for how animal studies should be planned, reported and reviewed, including humane endpoints, welfare monitoring and limits on tumor growth. The retraction note states that, as a result of the excessive tumor burden shown in the paper, the study does not appear to meet the animal ethics standards described in those guidelines.

The retraction is notable for the response of the author team. According to the notice, Xu Li, speaking on behalf of all the authors, stated that they disagree with the retraction. Disagreement between authors and journals is not uncommon in retraction cases, and journals typically publish the authors’ position alongside the retraction notice to make the record transparent. In this instance, the journal has recorded the authors’ objection while still removing the article from the body of credible scientific literature, leaving readers to weigh the dispute for themselves.

The research behind the paper originated from a collaboration spanning several Chinese institutions. The author group included DanPing Wang, ChenLi Su, Xiao Zhang, Wei Mao, XiaoQiang Dai, Li Xu and XiaoMin Si. Affiliations listed for the team include the Department of Oncology at Xianyang Central Hospital in Shaanxi Province, the Clinical Medicine College at Shaanxi University of Chinese Medicine, and a key laboratory at Yangzhou University dedicated to integrated traditional Chinese and Western medicine in the control of senile diseases. DanPing Wang and ChenLi Su were identified as having contributed equally to the work, with correspondence directed to Li Xu and XiaoMin Si.

The scientific premise of the retracted study touched on a question of real clinical importance. Buparlisib is one of a family of PI3K inhibitors developed to disrupt signaling pathways that drive tumor growth and survival. Resistance to such targeted agents remains a major obstacle in oncology, and proposed mechanisms of resistance attract intense interest because they can suggest combination strategies to overcome treatment failure. Eukaryotic elongation factor-2, the molecule implicated in the paper, is an essential component of the translational apparatus that converts messenger RNA into protein, and its regulation has previously been linked to stress responses in cancer cells. A credible demonstration that a PI3K inhibitor induces this factor and thereby contributes to treatment failure would have been a meaningful addition to the resistance literature.

That potential contribution is now in doubt. Retractions serve a specific function in the scientific record: they alert readers that a published article’s findings can no longer be trusted as reliable, whether because of errors, ethical violations or misconduct. In this case, the stated reason is not fraud or data fabrication but a failure of animal ethics compliance, specifically tumor burden beyond accepted limits in the animal experiments underpinning Figure 5. The distinction matters, because it underscores that scientific publishing increasingly treats ethical compliance as inseparable from scientific validity. A result obtained outside accepted welfare boundaries is regarded not merely as ethically problematic but as unfit for the literature.

The case also illustrates the practical reach of the ARRIVE 2.0 guidelines, which have become a benchmark that editors and reviewers consult when evaluating animal studies. By citing the framework directly in the retraction notice, the journal signaled that deviations from those standards are grounds for withdrawal even after publication. For researchers working with tumor-bearing animals, the message is that monitoring tumor size against predefined humane limits is not an administrative formality but a condition of publication. Journals and their editors are prepared to retract work, years of effort and all, when the welfare thresholds written into those guidelines are crossed.

For the field of lung cancer research, the retraction removes one proposed mechanism of resistance to a PI3K-targeted therapy from the pool of evidence that other scientists might build upon. The original article remains accessible as a retracted document, clearly flagged, so that readers who encounter it can understand its status. The episode serves as a reminder that the credibility of cancer biology depends not only on the ingenuity of its hypotheses but on the rigor and ethics of the experiments that support them, and that the machinery of scientific self-correction, though sometimes contested by authors, continues to operate when standards are not met.

Subject of Research: Retraction of a lung cancer study on buparlisib-induced eukaryotic elongation factor-2 expression due to animal ethics violations

Article Title: Retraction Note: Buparlisib induces eukaryotic elongation factor-2 expression to cause treatment failure for lung cancer cells

Article References: Wang, D., Su, C., Zhang, X., Mao, W., Dai, X., Xu, L., & Si, X. (2026). Retraction Note: Buparlisib induces eukaryotic elongation factor-2 expression to cause treatment failure for lung cancer cells. Molecular Genetics and Genomics, 301(1), Article 195. https://doi.org/10.1007/s00438-026-02522-z

Image Credits: AI Generated

DOI: 10.1007/s00438-026-02522-z

Keywords: retraction, buparlisib, eukaryotic elongation factor-2, lung cancer, treatment failure, animal ethics, tumor burden, ARRIVE 2.0, PI3K inhibitor, Molecular Genetics and Genomics, research integrity, targeted therapy